ResMed Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on October 30, 2026, reporting first-quarter fiscal 2027 financial results including net income of $418,413 thousand and a significant treasury stock repurchase.

Key Highlights

  • Net revenue of $1,414,814 thousand for the three months ended September 30, 2026, up from $1,335,582 thousand in the same period a year earlier, according to the filing.
  • Net income of $418,413 thousand for the quarter, compared with $348,536 thousand in the prior-year quarter, as reported in the condensed consolidated statements of operations.
  • Diluted earnings per share of $2.92 for the three months ended September 30, 2026, versus $2.37 in the prior-year period.
  • Treasury stock purchases of $854,744 thousand during the quarter, increasing treasury shares from 46,798,043 to 50,441,545.
  • Dividend of $0.66 per common share declared during the quarter, totaling $94,954 thousand.
  • Gain on divestment of subsidiaries of $61,784 thousand recognized in the quarter, with no comparable gain in the prior-year period.
  • 140,657,071 shares of common stock outstanding as of October 26, 2026, excluding 50,441,545 treasury shares.

ResMed Reports Q1 FY2027 Results: Revenue Growth, Large Buyback, and Subsidiary Divestiture Gain

According to the filing, ResMed Inc. (NYSE:RMD) generated net revenue of $1,414,814 thousand for the three months ended September 30, 2026, consisting of $1,259,802 thousand from Sleep and Breathing Health products and $155,012 thousand from Residential Care Software. In the comparable prior-year quarter, those segments contributed $1,169,446 thousand and $166,136 thousand, respectively. Total cost of sales was $544,247 thousand, yielding a gross profit of $870,567 thousand, compared with $817,664 thousand a year earlier.

The company reported income from operations of $452,984 thousand for the quarter. Total other income, net, was $86,171 thousand, which the filing attributes in part to a gain on divestment of subsidiaries of $61,784 thousand and interest income of $21,198 thousand. Income before income taxes was $539,155 thousand, and income taxes were $120,742 thousand, resulting in net income of $418,413 thousand. Basic earnings per share were $2.93 and diluted earnings per share were $2.92, based on basic shares outstanding of 142,989 thousand and diluted shares outstanding of 143,411 thousand.

On the balance sheet, the filing shows total assets of $8,211,811 thousand as of September 30, 2026, compared with $8,965,950 thousand at June 30, 2026. The decline reflects, in part, the completion of a divestiture: assets held for sale of $457,386 thousand and liabilities held for sale of $41,156 thousand that appeared on the June 30, 2026 balance sheet were both zero at September 30, 2026. Treasury stock purchases of $854,744 thousand during the quarter increased the treasury stock balance from $2,778,591 thousand to $3,633,335 thousand. Total stockholders' equity was $5,947,690 thousand at quarter end, down from $6,585,393 thousand at June 30, 2026.

What Was Disclosed

ResMed's 10-Q for the quarter ended September 30, 2026 disclosed quarterly revenue of $1,414,814 thousand, net income of $418,413 thousand, diluted EPS of $2.92, treasury stock repurchases of $854,744 thousand, a dividend of $0.66 per share, and a subsidiary divestiture gain of $61,784 thousand.